Potential COVID Drug May Raise Heart Risk: Study
The widely prescribed antibiotic azithromycin is being investigated as a COVID-19 treatment, but a new study warns it could increase the risk of heart problems. (Source: WebMD Health)
Source: WebMD Health - September 21, 2020 Category: Consumer Health News Source Type: news

Potential COVID-19 Drug Could Increase Heart Risk: Study
MONDAY, Sept. 21, 2020 -- The widely prescribed antibiotic azithromycin is being investigated as a COVID-19 treatment, but a new study warns it could increase the risk of heart problems. Researchers analyzed data from millions of patients (average... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 21, 2020 Category: General Medicine Source Type: news

Potential COVID-19 drug azithromycin may increase risk for cardiac events
(University of Illinois at Chicago) Azithromycin -- a commonly-prescribed antibiotic -- also is being investigated as a potential treatment for COVID-19. Researchers have found that azithromycin by itself is not associated with an increase in cardiac events; however, if the drug is taken with certain other drugs that affect the electrical functioning of the heart, then cardiac events increased. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2020 Category: International Medicine & Public Health Source Type: news

Azithromycin Fails to Help Hospitalized COVID-19 Patients Azithromycin Fails to Help Hospitalized COVID-19 Patients
The antibiotic azithromycin did not appear to provide any benefit to hospitalized COVID-19 patients who were having trouble breathing, according to a study in Brazil.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 14, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

More about chloroquine and hydroxychloroquine, CEBM (updated 30th August 2020)
VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - September 2, 2020 Category: Consumer Health News Source Type: news

Hydroxychloroquine plus azithromycin increases heart risk, finds global study
(Columbia University Irving Medical Center) In the largest observational study of hydroxychloroquine and azithromycin, the drug combination has been linked to significant cardiovascular risks, including death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2020 Category: International Medicine & Public Health Source Type: news

Hydroxychloroquine works in high-risk patients, and saying otherwise is dangerous
(Natural News) As of Wednesday, some 165,000 people in the United States have died from COVID-19. I have made the case in the American Journal of Epidemiology and in Newsweek that people who have a medical need to be treated can be treated early and successfully with hydroxychloroquine, zinc, and antibiotics such as azithromycin or doxycycline. I have also argued that these... (Source: NaturalNews.com)
Source: NaturalNews.com - August 14, 2020 Category: Consumer Health News Source Type: news

' Doubling Down' on Hydroxychloroquine QT Prolongation in COVID-19'Doubling Down' on Hydroxychloroquine QT Prolongation in COVID-19
Patients had progressively longer QT intervals with hydroxychloroquine plus azithromycin but also frequently received other drugs that had QT-prolonging effects in a new study.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 7, 2020 Category: Neurology Tags: Cardiology News Source Type: news

Study shows triple treatment including hydroxychloroquine and zinc leads to fewer hospitalizations
(Natural News) A new study shows that hospitalizations for coronavirus patients could be reduced by five times with the early use of zinc, azithromycin and a low dose of hydroxychloroquine. This is according to research led by Dr. Vladimir Zelenko, a primary care physician in New York, in collaboration with a pair of German doctors.... (Source: NaturalNews.com)
Source: NaturalNews.com - July 23, 2020 Category: Consumer Health News Source Type: news

February to March 2020 Saw Surge in Hydroxychloroquine Rx
WEDNESDAY, July 8, 2020 -- From February to March 2020, there was a considerable increase in the number of patients receiving outpatient prescriptions for hydroxychloroquine, chloroquine, and azithromycin, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2020 Category: Pharmaceuticals Source Type: news

US hydroxychloroquine, chloroquine, azithromycin outpatient prescriptions October 2019-March 2020
(JAMA Network) How the prescription of hydroxychloroquine and chloroquine to outpatients has changed in the United States during the COVID-19 pandemic is examined in this study. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 6, 2020 Category: International Medicine & Public Health Source Type: news

Study: Azithromycin doubles risk for cardiovascular death versus amoxicillin
People who take the commonly prescribed antibiotic azithromycin were nearly twice as likely to die from a heart attack, stroke or other cardiovascular event than users of amoxicillin, a study found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 18, 2020 Category: Consumer Health News Source Type: news

CVD, Non-CVD Mortality Increased With Azithromycin Use
WEDNESDAY, June 17, 2020 -- Outpatient azithromycin use is associated with an increased risk for cardiovascular and noncardiovascular mortality, according to a study published online June 17 in JAMA Network Open. Jonathan G. Zaroff, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 17, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2020 Category: International Medicine & Public Health Source Type: news

U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients. Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care. The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news

More evidence of no survival benefit in COVID-19 patients receiving hydroxychloroquine
(Cell Press) A study of electronic medical records from US Veterans Health Administration medical centers has found that hydroxychloroquine -- with or without azithromycin -- did not reduce the risk of ventilation or death and was associated with longer length of hospital stay. This analysis, published June 5 in the journal Med, is the first in the US to report data on hydroxychloroquine outcomes for COVID-19 from a nationwide integrated health system. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 5, 2020 Category: Infectious Diseases Source Type: news

First do no harm -- researchers urge halt in prescribing hydroxycholoroquine for COVID-19
(Florida Atlantic University) Researchers urge a moratorium on prescribing chloroquine or hydroxychloroquine, with or without azithromycin, to treat or prevent COVID-19, and caution that the reassuring safety profile of hydroxychloroquine may be more apparent than real. Safety data derive from decades of prescriptions by clinicians, primarily for their patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle age women, who are at very low risk of fatal heart outcomes due to hydroxychloroquine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 3, 2020 Category: Infectious Diseases Source Type: news

More about chloroquine and hydroxychloroquine, CEBM
VERDICT: The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may be increased in patients who are acutely ill with severe COVID-19, in many of whom high doses are being used. Macrolide antibacterial drugs, such as azithromycin, clarithromycin, ery...
Source: Current Awareness Service for Health (CASH) - June 1, 2020 Category: Consumer Health News Source Type: news

CV Toxicity Tied to Azithromycin and/or Hydroxychloroquine
THURSDAY, May 28, 2020 -- Hydroxychloroquine and azithromycin may have a serious adverse impact on the cardiovascular system, according to a research letter published online May 22 in Circulation. Lee S. Nguyen, M.D., from Sorbonne... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis
Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2020 Category: Cancer & Oncology Authors: Ryan McDonald Source Type: news

Hydroxychloroquine-azithromycin combo may be potentially lethal: Study
Hydroxychloroquine and azithromycin, alone or in combination, have been proposed for treatment of COVID-19 patients, the researchers said. They explained that reports of potentially lethal acute cardiac proarrhythmogenic effects -- promoting irregular heart rhythms -- have been described mainly with azithromycin but also with hydroxychloroquine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 26, 2020 Category: Pharmaceuticals Source Type: news

Malaria Drug Taken by Trump Is Tied to Increased Risk of Heart Problems and Death in New Study
The drugs did not help coronavirus patients, and should not be used outside clinical trials, researchers said. (Source: NYT Health)
Source: NYT Health - May 22, 2020 Category: Consumer Health News Authors: Denise Grady Tags: Hydroxychloroquine (Drug) Azithromycin (Drug) Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Malaria Clinical Trials Food and Drug Administration Lancet, The (Journal) Trump, Donald J your-feed-healthcare Source Type: news

President Trump Defends His Hydroxychloroquine Use Amid Concerns, Says ‘So Far I Seem to Be O.K.’
(WASHINGTON) — President Donald Trump emphatically defended himself Tuesday against criticism from medical experts that his announced use of a malaria drug against the coronavirus could spark wide misuse by Americans of the unproven treatment with potentially fatal side effects. Trump’s revelation a day earlier that he was taking hydroxychloroquine caught many in his administration by surprise and set off an urgent effort by officials to justify his action. But their attempt to address the concerns of health professionals was undercut by the president himself. He asserted without evidence that a study raising a...
Source: TIME: Health - May 20, 2020 Category: Consumer Health News Authors: ZEKE MILLER, MARILYNN MARCHIONE and JONATHAN LEMIRE / AP Tags: Uncategorized COVID-19 Donald Trump News Desk wire Source Type: news

What to Know About Hydroxychloroquine
Here are the facts on hydroxychloroquine, which the president has promoted to fight Covid-19 despite warnings from the F.D.A. that it can cause heart problems. (Source: NYT Health)
Source: NYT Health - May 19, 2020 Category: Consumer Health News Authors: Denise Grady, Katie Thomas, Patrick J. Lyons and Neil Vigdor Tags: Hydroxychloroquine (Drug) Coronavirus (2019-nCoV) Azithromycin (Drug) Drugs (Pharmaceuticals) Preventive Medicine Research Hospitals Clinical Trials Rumors and Misinformation Rheumatoid Arthritis Lupus Erythematosus Food and Drug Adm Source Type: news

Hydroxychloroquine No Aid for COVID - Related Mortality
Hydroxychloroquine alone or with azithromycin associated with abnormal electrocardiogram findings (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 18, 2020 Category: Respiratory Medicine Tags: Cardiology, Infections, Internal Medicine, Critical Care, Emergency Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Hydroxychloroquine No Aid for COVID-Related Mortality
MONDAY, May 18, 2020 -- Treating hospitalized COVID-19 patients with hydroxychloroquine, azithromycin, or both is not associated with improvements in in-hospital mortality, according to a study published online May 11 in the Journal of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2020 Category: Pharmaceuticals Source Type: news

NIH Launches Trial of Hydroxychloroquine, Azithromycin for COVID - 19
Trial will enroll 2,000 patients with SARS - COV - 2 who have fever, cough, and/or shortness of breath (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 15, 2020 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Pharmacy, Pulmonology, Institutional, Source Type: news

NIH Launches Trial of Hydroxychloroquine, Azithromycin for COVID-19
FRIDAY, May 15, 2020 -- The National Institute of Allergy and Infectious Diseases (NIAID) announced it is sponsoring a phase 2b clinical trial to evaluate the efficacy and safety of hydroxychloroquine and azithromycin in preventing hospitalization... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 15, 2020 Category: Pharmaceuticals Source Type: news

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
(University of California - San Diego) The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites and is led by Davey Smith, MD, of UC San Diego School of Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 15, 2020 Category: Infectious Diseases Source Type: news

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat coronavirus patients
On Thursday, the NIH announced it has begun a clinical trial testing a combination of the antibiotic azithromycin and the anti-malaria drug hydroxychloroquine in coronavirus patients. (Source: the Mail online | Health)
Source: the Mail online | Health - May 15, 2020 Category: Consumer Health News Source Type: news

NIH to study malaria drug championed by President Trump against COVID-19
The National Institutes of Health (NIH) said on Thursday it began a study to evaluate the combination of antibiotic azithromycin and malaria drug hydroxychloroquine, which was previously touted by U.S. President Donald Trump as a "game changer", for the treatment of COVID-19. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
Study enrolling adults with mild to moderate COVID-19 in the United States. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 14, 2020 Category: American Health Source Type: news

Drug vignettes: Azithromycin, CEBM
Azithromycin is a macrolide antibacterial drug, derived from erythromycin, licensed in the USA and in the UK, and used to treat bacterial infections. It has been used in combination with hydroxychloroquine in the treatment of COVID-19. However, there is an adverse drug –drug interaction between the two, which contraindicates their combined use. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 14, 2020 Category: Consumer Health News Source Type: news

ACTG launches clinical trial testing treatment for COVID-19
(University of California - Los Angeles Health Sciences) The AIDS Clinical Trials Group (ACTG) has initiated a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2020 Category: Infectious Diseases Source Type: news

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2020 Category: Infectious Diseases Source Type: news

Fact Sheet for Healthcare Providers: G Medical VSMS ECG Patch
Source: U.S. Food and Drug Administration (FDA). Published: 5/14/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the G Medical VSMS ECG Patch. The VSMS Patch is authorized for emergency use in the hospital setting for remote monitoring of the QT interval of an electrocardiogram (ECG) in general care (i.e., not in the intensive care unit) patients who are 18 years of age or older and are undergoing treatment for COVID-19 using drugs that can prolong the QT intervals and may cause life-threatening arrhythmias ( e.g., hydroxychlor...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 14, 2020 Category: International Medicine & Public Health Source Type: news

Zinc might boost effectiveness of malaria drug against COVID-19, experts say
Adding zinc to hydroxychloroquine and azithromycin might help the drug combination resolve some of the symptoms of COVID-19, a study posted online this week said. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 13, 2020 Category: Consumer Health News Source Type: news

Addition of Zinc May Benefit Some Being Treated for COVID - 19
Some outcomes improved with addition of zinc sulfate to hydroxychloroquine and azithromycin (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 13, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Addition of Zinc May Benefit Some Being Treated for COVID-19
WEDNESDAY, May 13, 2020 -- For hospitalized patients with COVID-19, the addition of zinc sulfate to hydroxychloroquine and azithromycin may improve some outcomes, according to a study not yet peer reviewed and posted on medRxiv.org. Philip M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) ACP: Evidence does not support the use of hydroxychloroquine alone or in combination with azithromycin for prophylaxis or treatment of COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 13, 2020 Category: Infectious Diseases Source Type: news

University of Kentucky launches clinical trial to evaluate new COVID-19 treatments
(University of Kentucky) The trial will investigate the effectiveness of azithromycin, ivermectin and camostat mesylate--drugs that could inhibit replication of SARS-CoV-2, the virus that causes the disease. The three will be tested either as stand-alone therapies or in combination with the antimalarial drug hydroxychloroquine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 11, 2020 Category: Infectious Diseases Source Type: news

TGen and HonorHealth initiate COVID-19 combination therapy of atovaquone and azithromycin
(The Translational Genomics Research Institute) The HonorHealth Research Institute and HonorHealth announced today the successful enrollment on a novel combination of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection. The clinical trial, conducted in collaboration with the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is funded as an investigator-initiated clinical trial by HonorHealth Research Institute. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 6, 2020 Category: Infectious Diseases Source Type: news

Fact Sheet for Healthcare Providers: PhysiolGuard ECG-QT Analysis System
Source: U.S. Food and Drug Administration (FDA). Published: 5/5/2020. This four-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the PhysiolGuard ECG-QT Analysis System when used in the hospital setting for remote monitoring and detection of changes in the QT interval of an electrocardiogram (ECG) in general care (i.e., not in the intensive care unit) patients who are 18 years of age or older and are undergoing treatment for COVID-19 drugs that can prolong QT intervals and may cause life threatening arrhythmias (e.g., hydroxychloroquine or chlor...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Assessment of QT intervals in case series of patients with COVID-19 treated with hydroxychloroquine alone or in combination with azithromycin
(JAMA Network) Case series assesses QT intervals for French patients with coronavirus disease 2019 (COVID-19) treated with hydroxychloroquine alone or in combination with azithromycin. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 1, 2020 Category: Infectious Diseases Source Type: news

QT interval prolongation, hydroxychloroquine, azithromycin in hospitalized patients with COVID-19
(JAMA Network) This observational study examines the association of hydroxychloroquine or hydroxychloroquine and azithromycin with QT prolongation in adult patients hospitalized with coronavirus disease 2019 (COVID-19). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 1, 2020 Category: Infectious Diseases Source Type: news

Hydroxychloroquine linked to increased risk of cardiac arrhythmias
(Beth Israel Deaconess Medical Center) In a brief report published today in JAMA Cardiology, a team of pharmacists and clinicians at Beth Israel Deaconess Medical Center (BIDMC), part of Beth Israel Lahey Health, found evidence suggesting that patients who received hydroxychloroquine for COVID-19 were at increased risk of electrical changes to the heart and cardiac arrhythmias. The combination of hydroxychloroquine with azithromycin was linked to even greater changes compared to hydroxychloroquine alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2020 Category: International Medicine & Public Health Source Type: news

What is the evidence for use of macrolide antibiotics for treatment of COVID-19?, CEBM
We identified three studies, two in vitro and one in vivo, assessing the use of macrolide antibiotics for the treatment of COVID-19. Each of these studies assessed treatment with azithromycin. The evidence from the in vivo study and one in vitro study suggest a possible synergy between azithromycin and hydroxychloroquine. However, the in vivo study had a small number of participants and was methodologically flawed; the findings must therefore be treated with caution. The two in vitro studies provided conflicting results regarding the activity of azithromycin alone against SARS-CoV-2; one found that azithromycin alone had a...
Source: Current Awareness Service for Health (CASH) - April 29, 2020 Category: Consumer Health News Source Type: news

Prescriptions Surged as Trump Praised Drugs in Coronavirus Fight
Prescriptions for two antimalarial drugs jumped by 46 times the average when the president promoted them on TV. There ’s no proof they work against Covid-19. (Source: NYT Health)
Source: NYT Health - April 25, 2020 Category: Consumer Health News Authors: Ellen Gabler and Michael H. Keller Tags: Drugs (Pharmaceuticals) Hydroxychloroquine (Drug) Azithromycin (Drug) Coronavirus (2019-nCoV) United States Politics and Government Autoimmune Diseases Lupus Erythematosus Rheumatoid Arthritis Trump, Donald J Food and Drug Administration Source Type: news

F.D.A. Warns of Heart Problems From Malaria Drugs Used for Coronavirus
The drugs, hydroxychloroquine and chloroquine, have been repeatedly promoted by President Trump. But they should be used only in clinical trials or hospitals, the agency said. (Source: NYT)
Source: NYT - April 25, 2020 Category: American Health Authors: Denise Grady Tags: Hydroxychloroquine (Drug) Food and Drug Administration National Institute of Allergy and Infectious Diseases Azithromycin (Drug) Coronavirus (2019-nCoV) Trump, Donald J Biomedical Advanced Research and Development Authority Nature Medicine ( Source Type: news